Press release
New Product Developments will Drive the Skin and Soft Tissue Infection Treatment Market
Skin and soft tissue infections (SSTIs) may be caused by any of the pathogenic microorganisms which include Staphylococcus aureus, Streptococcus pyogene, gram-negative bacilli, Pseudomonas aeruginosa, beta-hemolytic streptococci, Enterococcus, streptococci, staphylococci, Peptostreptococcus, Bacteroides, Clostridium and S. pyogenes. Methicillin-resistant Staphylococcus aureus (MRSA) and streptococci are the most common organisms causing skin and soft tissue infections (SSTIs).
Obtain Report Details @ http://www.transparencymarketresearch.com/skin-soft-tissue-infection-treatment-market.html
The market for skin and soft tissue infections treatment is analyzed based on the medications used for its treatment which includes antibiotics and anti-fungal agents. Traditionally, use of beta-lactam antibiotics has proved to be beneficial against various skin and soft tissue infections. However, with rising use of these traditional medications has led to resistance of these bacteria against the beta-lactam antibiotics.
Moreover, new strains of infectious bacteria urge the need for development of new therapies. Consequently physicians have started using the third-generation antibiotics such as cephalosporins, fluoroquinolones or extended-spectrum agents such as amoxicillin and clavulanic acid. The selection of an appropriate drug depends on the causative microorganism. Besides medications, imaging tools and surgical methods are also practiced for the treatment of skin and soft tissue infections (SSTIs).
The rising incidence of Methicillin-resistant Staphylococcus aureus (MRSA) infections has resulted in the need for new therapies to combat the serious skin and soft tissue infections. In addition, new product developments will drive the skin and soft tissue infections treatment market. Recently, in February 2014, Cubist Pharmaceuticals, Inc. announced that its Marketing Authorization Application (MAA) for investigational candidate tedizolid phosphate has been accepted by the European Medicines Agency (EMA) for review. With a decision expected from the European Commission (EC) during the first half of 2015, the company seeks to market its new product for the treatment of skin and soft tissue infections.
Prior to EMA, the U.S. FDA accepted company’s New Drug Application (NDA) for review and the company had also planned for submitting a New Drug Submission (NDS) in Canada in 2014 for tedizolid intended for the treatment of skin and soft tissue infections. Moreover, in December 2013, Durata Therapeutics, Inc. announced the acceptance of its Marketing Authorization Application (MAA) for dalbavancin, intended for the treatment of skin and soft tissue infections, by the European Medicines Agency (EMA) for review.
Make an Enquiry @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13349
The Infectious Diseases Society of America has recently released guidelines for the diagnosis and management of skin and soft tissue infections (SSTIs). This practice guideline is to guide the physicians in proper diagnosis and efficient treatment of the skin and soft tissue infections and avoid serious consequences. Based on geography, the skin and soft tissue infections treatment market is analyzed into North America, Europe, Asia-Pacific and Rest of the World.
Some of the companies engaged in the development of skin and soft tissue infection (SSTI) treatment medications include Cubist Pharmaceuticals, Inc., Wockhardt Limited, Atox Bio Inc., Durata Therapeutics, Inc., Basilea Pharmaceutica AG, and Melinta Therapeutics Inc.
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release New Product Developments will Drive the Skin and Soft Tissue Infection Treatment Market here
News-ID: 550225 • Views: …
More Releases from Transparency Market Research
Gas Compressor Market Outlook 2036: Global Industry Expected to Reach US$ 41.0 B …
The global gas compressor market was valued at US$ 23.2 Bn in 2025 and is projected to reach US$ 41.0 Bn by 2036, expanding at a compound annual growth rate (CAGR) of 5.3% from 2026 to 2036. This steady growth trajectory reflects the structural importance of gas compression systems across upstream, midstream, and downstream gas value chains. Rising natural gas consumption, expansion of pipeline and LNG infrastructure, and national energy…
Anesthesia Drugs Market to be Worth USD 12.6 Bn by 2036 - By Drug / By Applicati …
The global anesthesia drugs market was valued at US$ 7.6 billion in 2025 and is projected to reach US$ 12.6 billion by 2036, expanding at a compound annual growth rate (CAGR) of 4.7% from 2026 to 2036. This steady growth trajectory reflects the essential and non-substitutable role of anesthesia drugs in modern healthcare systems. As surgical interventions continue to rise globally-across both elective and emergency procedures-the demand for safe, effective,…
Single-Atom Catalysts Market Size is Expected to Expand from US$ 177.8 Million t …
The global single-atom catalysts (SACs) market is poised for remarkable growth as industries seek highly efficient, cost-effective, and sustainable catalytic solutions. Valued at US$ 177.8 million in 2025, the market is projected to reach US$ 1,000.2 million by 2036, expanding at a robust compound annual growth rate (CAGR) of 17.0% from 2026 to 2036. This rapid expansion reflects the growing importance of advanced catalysis in energy, chemicals, environmental protection, and…
Non-specific Endonuclease Market to Reach USD 726.6 Million by 2036, Supported b …
The non-specific endonuclease market is witnessing steady growth, driven by the expanding use of molecular biology tools across biotechnology, pharmaceuticals, diagnostics, and academic research. Non-specific endonucleases are enzymes that cleave nucleic acids without requiring a specific recognition sequence, making them highly valuable for applications such as DNA/RNA degradation, sample preparation, viscosity reduction, and contamination control. Their broad activity profile differentiates them from restriction enzymes and enables versatile usage across multiple…
More Releases for SSTI
Skin and Soft Tissue Infections Market Trends, Growth Drivers & Forecast 2024-20 …
The Global Skin and Soft Tissue Infections Market reached US$ 11,283.71 million in 2023 and is expected to reach US$ 21,708.55 million by 2031, growing at a CAGR of 8.8% during the forecast period 2024-2031.
The Skin and Soft Tissue Infections Market Report by DataM Intelligence offers comprehensive insights into the latest market trends, key growth drivers, and emerging challenges. Crafted to support smarter and faster decision-making, our reports blend in-depth…
Comprehensive Growth Forecast for Skin and Soft Tissue Infection Treatment Marke …
Skin and Soft Tissue Infection Treatment Market Insights: Trends, Drivers, and Outlook 2024 - 2031
Skin and Soft Tissue Infection Treatment Market Scope: Unveiling Today's Trends
Skin and Soft Tissue Infection Treatment involves therapies and medications aimed at addressing infections affecting the skin and underlying tissues. The market for these treatments has been experiencing significant growth, driven by rising incidences of surgical site infections, increasing awareness of antibiotic resistance, and the ongoing…
Insights on the Linezolid Market to 2027 | Industry Statistics, Emerging Demands …
The global Linezolid market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Linezolid is an antibiotic drug that is used for the treatment of serious bacterial infections such as gram-positive bacteria, pneumonia, skin infections, and infections that are resistant to other antibiotics by stopping the growth of bacteria. This drug is either consumed by mouth or by injecting directly into the vein. The major factor…
Linezolid Drug Market Size, Key Trends, Challenges and Standardization, Research …
Complete study of the global Linezolid Drug market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Linezolid Drug industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the researchers. They have also…
Skin and Soft Tissue Infection Treatment Market: Evolving Technology, Trends and …
Skin and Soft Tissue Infection Treatment Market: Overview
Skin and soft tissue infections (SSTIs) are one of the most common infections present in inpatient as well as outpatients. Skin and soft tissue infections (SSTIs) comprise of various minor and major infections of skin, fascia, subcutaneous tissue and muscle. These infections include such as impetigo, folliculitis, furuncles, carbuncles, erysipelas, cellulitis, necrotizing fasciitis and pyomyositis. These infections may be associated with an…
Skin and Soft Tissue Infection Treatment Market: Key Futuristic Trends And Compe …
Skin and Soft Tissue Infection Treatment Market: Overview
Skin and soft tissue infections (SSTIs) are one of the most common infections present in inpatient as well as outpatients. Skin and soft tissue infections (SSTIs) comprise of various minor and major infections of skin, fascia, subcutaneous tissue and muscle. These infections include such as impetigo, folliculitis, furuncles, carbuncles, erysipelas, cellulitis, necrotizing fasciitis and pyomyositis. These infections may be associated with an underlying…
